When should therapeutic intervention take place for men on active surveillance?

The fact of the matter is that, as yet, we don’t have a good answer for this question, and it may be many years before we do. The reasons for this are numerous, but we are beginning to get some of the information we need to clarify the situation. … READ MORE …

Risk category definitions, trial protocols, and clinical outcomes

Recent research data raise questions as to whether clinical trial protocols — and their results — are being skewed (notably for men with so-called “intermediate-risk” disease) by current definitions of risk category. … READ MORE …

Prostate cancer news reports: Wednesday, September 23, 2009

Today’s news reports cover items on:

  • Extent and number of biopsy cores and eligibility for active surveillance
  • Intermittent vs. complete androgen deprivation
  • Hormone therapy and risk for cardiovascular disease and death
  • Surrogate markets for disease progression in men with CRPC … READ MORE …

Get every new post delivered to your Inbox.

Join 1,254 other followers